1. Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19
- Author
-
Saurav Chatterjee, Matthew A. Barish, Thomas McGinn, Martin Lesser, Dimitrios Giannis, Alex C. Spyropoulos, Nina Kohn, Mark Goldin, Stuart L. Cohen, Eugenia Gianos, Kevin Coppa, and Jamie S. Hirsch
- Subjects
Male ,medicine.medical_specialty ,Deep vein ,New York ,030204 cardiovascular system & hematology ,Article ,law.invention ,Fibrin Fibrinogen Degradation Products ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,law ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Mortality ,Retrospective Studies ,Venous Thrombosis ,SARS-CoV-2 ,business.industry ,Incidence ,Mortality rate ,Incidence (epidemiology) ,COVID-19 ,Outpatient ,Thrombosis ,Retrospective cohort study ,Hematology ,Middle Aged ,Protective Factors ,medicine.disease ,Intensive care unit ,Pulmonary embolism ,Intensive Care Units ,Venous thrombosis ,Outcome and Process Assessment, Health Care ,medicine.anatomical_structure ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Pulmonary Embolism ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors ,Venous thromboembolism - Abstract
Venous thromboembolism (VTE) has emerged as an important issue in patients with COVID-19. The purpose of this study is to identify the incidence of VTE and mortality in COVID-19 patients initially presenting to a large health system. Our retrospective study included adult patients (excluding patients presenting with obstetric/gynecologic conditions) across a multihospital health system in the New York Metropolitan Region from March 1-April 27, 2020. VTE and mortality rates within 8 h of assessment were described. In 10,871 adults with COVID-19, 118 patients (1.09%) were diagnosed with symptomatic VTE (101 pulmonary embolism, 17 deep vein thrombosis events) and 28 patients (0.26%) died during initial assessment. Among these 146 patients, 64.4% were males, 56.8% were 60 years or older, 15.1% had a BMI > 35, and 11.6% were admitted to the intensive care unit. Comorbidities included hypertension (46.6%), diabetes (24.7%), hyperlipidemia (14.4%), chronic lung disease (12.3%), coronary artery disease (11.0%), and prior VTE (7.5%). Key medications included corticosteroids (22.6%), statins (21.2%), antiplatelets (20.6%), and anticoagulants (20.6%). Highest D-Dimer was greater than six times the upper limit of normal in 51.4%. Statin and antiplatelet use were associated with decreased VTE or mortality (each p
- Published
- 2021
- Full Text
- View/download PDF